AstraZeneca Pharma India Limited will launch Datverzo (datopotamab deruxtecan), a targeted therapy for advanced HR-positive, HER2-negative breast cancer, in India in November 2026, the company told stock exchanges on 7 November 2026. The update came two days after the drugmaker reported a 30.4% rise in Q2 FY27 revenue to ₹729 crore.

AstraZeneca Datverzo launch: what the filing says

In its exchange intimation, the company said the Drugs Controller General of India (DCGI) granted Datverzo import and market permission in Form CT-20, which it had disclosed on 17 December 2025. Commercial launch will now follow this month.

Datverzo is approved for adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+ or IHC 2+/ISH-negative) who have already received endocrine-based therapy and chemotherapy for advanced disease. The filing did not disclose pricing.

The launch adds to an active period for oncology pricing in India. Trade margin caps on 137 anti-cancer drugs take effect on 9 November, as covered in our report on cancer drug price cuts saving ₹3,502 crore a year.

AstraZeneca Pharma India Q2 FY27 results at a glance

The company announced its results for the July–September 2026 quarter on 5 November 2026:

• Revenue from operations: ₹729 crore, up 30.4% from ₹559 crore a year earlier
• EBITDA: ₹95 crore, up 26.7%, with margin at 13.1% against 13.4%
• Net profit: ₹62.3 crore, up 14.9% from ₹54.2 crore
• First-half FY27 revenue: ₹1,411.9 crore, up 30%

The company said growth came from its oncology, biopharmaceuticals and rare disease portfolios. Results also included exceptional items linked to the closure of its Bengaluru manufacturing site, where operations ceased in the June 2025 quarter and assets are being sold.

Which oncology approvals came during the quarter?

During Q2, AstraZeneca Pharma India received approvals for trastuzumab deruxtecan in three HER2-positive breast cancer settings: after taxane, trastuzumab and pertuzumab (THP) for Stage II or III early disease; for early disease with residual invasive cancer after neoadjuvant treatment; and with pertuzumab as first-line treatment for unresectable or metastatic disease. It also won approval for benralizumab in hypereosinophilic syndrome for patients aged 12 and above.

Praveen Rao Akkinepally, Country President and Managing Director, said the growth “demonstrates the strength of AstraZeneca’s science-led portfolio” and that the company is “accelerating our efforts across oncology, biopharmaceuticals and rare disease.” Akkinepally took charge after AstraZeneca Pharma India appointed him Managing Director in June 2025.

Why it matters for India’s pharma industry

Antibody-drug conjugates such as datopotamab deruxtecan and trastuzumab deruxtecan are reshaping breast cancer care, and multinational launches in India increasingly sit alongside tighter price regulation. AstraZeneca recently won Delhi High Court relief in a ₹151 crore NPPA inhaler case, and NPPA has also issued trade margin compliance FAQs for cancer drugs, showing how closely oncology portfolios are now watched.

Key takeaways

• Datverzo (datopotamab deruxtecan) launches in India in November 2026 for previously treated HR+/HER2- metastatic breast cancer.
• AstraZeneca Pharma India’s Q2 FY27 revenue rose 30.4% to ₹729 crore and net profit rose 14.9% to ₹62.3 crore.
• Oncology approvals for trastuzumab deruxtecan widened the company’s HER2-positive breast cancer portfolio.

FAQ

When will Datverzo be available in India?

AstraZeneca Pharma India said it will launch Datverzo in November 2026, following DCGI import and market permission.

Who is Datverzo approved for?

Adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy.

Featured image: AstraZeneca’s Academy House building in Cambridge, UK. Photo: D Wells, via Wikimedia Commons (CC BY-SA 4.0)

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!